Three types of FDA-approved drugs, that is, tyrosine kinase inhibitors (TKIs) (sorafenib, regorafenib, cabozantinib, and lenvatinib), immune checkpoint inhibitors (ICIs) (nivolumab and pembrolizumab), and vascular endothelial growth factor inhibitors (bevacizumab) have been used for advanced HCC (4). The gene discussed is VEGFA; the disease is hepatocellular carcinoma.